Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Cancer Immunology & Therapy (2023) Volume 6, Issue 5

The immune system's role in targeting cancer.

Joana Lichty *

Department of Pathology and Molecular Medicine, McMaster University, Canada

*Corresponding Author:
Joana Lichty
Department of Pathology and Molecular Medicine, McMaster University, Canada

Received: 04-Oct -2023, Manuscript No. AAJCIT-23- 117711; Editor assigned: 05-Oct-2023, PreQC No. AAJCIT-23- 117711 (PQ); Reviewed:19-Oct-2023, QC No. AAJCIT-23- 117711; Revised:24-Oct-2023, Manuscript No. AAJCIT-23- 117711 (R); Published:31-Oct-2023, DOI:10.35841/aara-6.5.168

Citation: Lichty J, The immune system's role in targeting cancer. J Cancer Immunol Ther. 2023;6(5):168

Visit for more related articles at Journal of Cancer Immunology & Therapy


Cancer, a formidable adversary, has long posed a challenge to the field of medicine. Traditional treatments such as surgery, chemotherapy, and radiation have made significant strides in extending and improving the lives of cancer patients. However, they often come with debilitating side effects and limited efficacy, especially in advanced cases. In recent years, the immune system has taken center stage as a potent weapon against cancer. This article delves into the vital role of the immune system in targeting and combating cancer. The immune system is an intricate network of cells, tissues, and organs that work together to protect the body against harmful invaders. It can recognize and eliminate foreign substances, including bacteria, viruses, and even cancer cells. The immune system's natural ability to distinguish between self and non-self is a fundamental line of defense against diseases. However, cancer cells are often cunning, evading detection and suppressing the immune response [1].

Cancer immunology is the field dedicated to unraveling the complexities of the immune system's response to cancer. It encompasses a range of strategies, all aimed at enhancing the immune system's ability to recognize and destroy cancer cells. One of the most promising approaches is immune checkpoint inhibitors. These medications work by blocking the molecular brakes that cancer cells use to evade immune detection. By releasing these brakes, immunotherapy unleashes the immune system's full potential to identify and destroy the cancer. Another groundbreaking advancement in cancer immunology is CAR-T cell therapy. In this innovative treatment, a patient's own T cells are genetically modified to express chimeric antigen receptors (CARs) that allow them to target and attack cancer cells specifically. CAR-T cell therapy has shown remarkable success in treating specific forms of leukemia and lymphoma, offering new hope to patients who had exhausted conventional treatment options [2].

One of the most compelling aspects of cancer immunology is the potential for personalized treatment. Unlike traditional treatments, which are often applied uniformly to all patients, immunotherapy can be tailored to an individual's unique genetic and immunological profile. This precision approach reduces the risk of adverse effects and increases the likelihood of a successful treatment outcome. The prospect of providing treatments highly tailored to a patient's needs represents a significant shift in cancer therapy. Immunotherapy has achieved remarkable results in various cancer types. For example, in advanced melanoma, an aggressive form of skin cancer, immune checkpoint inhibitors have led to long-term remissions in a substantial number of patients. Similarly, CAR-T cell therapy has shown great promise in treating specific forms of leukemia and lymphoma, often resulting in complete remissions. These success stories provide compelling evidence of the transformative potential of cancer immunology in cancer treatment [3].

Researchers are actively exploring the synergistic effects of combining immunotherapy with traditional treatments. In some cases, chemotherapy or radiation therapy can create a more favorable environment for immunotherapy to work effectively. The combination of treatments offers a comprehensive approach to cancer, attacking the disease from multiple angles and increasing the likelihood of a positive outcome [4].

In cases of certain hematologic cancers, such as leukemia and lymphoma, a combination of chemotherapy and CAR-T cell therapy has shown exceptional results, including complete remissions. For some head and neck cancers, radiation therapy combined with immunotherapy has enhanced the therapeutic effect and improved patient outcomes. While the synergy of conventional and immunotherapy is promising, challenges remain. Not all patients respond equally to these combinations, and some experience significant side effects. Ongoing research is focused on: Researchers are working to identify biomarkers and patient characteristics that can predict which patients are most likely to respond to combination therapies. Efforts are being made to reduce the side effects associated with combination therapies, ensuring that the benefits outweigh the potential harms. Collaboration between pharmaceutical companies, government agencies, and healthcare organizations is vital to ensure that these combination therapies are accessible to a broader range of patients [5].


The immune system's role in targeting cancer is a remarkable and revolutionary approach to cancer treatment. By enhancing the body's innate defense mechanisms, it offers personalized treatment options and the potential for long-term remission in various cancer types. Although challenges persist, the dedication and innovation of researchers and clinicians in the field of cancer immunology hold the promise of a brighter future for cancer patients around the world. As we continue to unlock the potential of the immune system in targeting and combating cancer, we move closer to transforming the landscape of cancer treatment and providing renewed hope to those affected by this formidable disease.


  1. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19-20):1267-84.
  2. Indexed at, Google Scholar, Cross Ref

  3. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24-37.
  4. Indexed at, Google Scholar, Cross Ref

  5. Li K, Zhang Z, Mei Y, et al. Targeting the innate immune system with nanoparticles for cancer immunotherapy. J Mater Chem B. 2022;10(11):1709-33.
  6. Indexed at, Google Scholar, Cross Ref

  7. Adam JK, Odhav B, Bhoola KD. Immune responses in cancer. Pharmacol Ther. 2003;99(1):113-32.
  8. Indexed at, Google Scholar, Cross Ref

  9. Kelly RJ, Gulley JL, Giaccone G. Targeting the immune system in non–small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer. 2010;11(4):228-37.
  10. Indexed at, Google Scholar, Cross Ref

Get the App